FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 32 of 40
Mar 13, 2026In a significant shift in cardiovascular health strategy, cardiology groups have updated guidelines recommending adults from age 30 begin assessing their cholesterol risk. This recommendation could lead to earlier preventative treatments, potentially reducing the long-term incidence of heart disease and stroke.
Mar 13, 2026Vaccine experts and the FDA committee emphasize the importance of timely flu shot development to mitigate seasonal influenza impact. This advisory highlights regulatory and logistical considerations coinciding with ongoing debates on vaccination and public health policies.
Mar 12, 2026Following the FDA’s inaugural public listening meeting on data-sharing practices in the cell and gene therapy sector, draft guidance has emerged. However, this move has spurred debate on whether shared evidence and prior knowledge will genuinely expedite therapeutic advancements or introduce complications in rare disease research and development.
Mar 11, 2026In a surprising regulatory move, the FDA has greenlighted leucovorin for treatment of a rare disorder despite the lack of conventional trial data usually required for such decisions. This approval marks a significant shift in how therapies for rare diseases may be evaluated and authorized, balancing urgent patient needs with evidentiary rigour.
Mar 9, 2026AstraZeneca is facing a pivotal review as the U.S. Food and Drug Administration (FDA) prepares to hold the first cancer advisory panel meeting in nine months. The committee will evaluate the applications for camizestrant, an oral selective estrogen receptor degrader (SERD) for breast cancer, and Truqap, an AKT inhibitor aimed at prostate cancer treatment. This meeting underscores the critical role that advisory panels play in guiding regulatory decisions for cutting-edge oncology drugs.
Mar 9, 2026The bipartisan Break Up Big Medicine Act aims to dismantle the growing influence of vertically integrated healthcare companies. However, experts suggest that despite recent wins on PBM transparency and delinking, the political and industry resistance make passing this legislation unlikely. Understanding these dynamics is essential for stakeholders seeking meaningful healthcare reform.
Mar 7, 2026The newly appointed federal autism advisory board's cancellation of its first public meeting since its overhaul raises questions about the committee's future public engagement and regulatory direction on autism-related policies and initiatives.
Mar 7, 2026Prasad’s leadership at CBER was characterized by firm stances on drug approvals, especially for rare diseases, which sparked significant debate within the agency and the biopharma sector. His exit marks a pivotal moment for the FDA’s biologics regulatory landscape.
Mar 6, 2026The regulation of clinical trials for gene therapies presents unique ethical and procedural challenges. UniQure’s pursuit of a sham-controlled Phase 3 trial for AMT-130 in Huntington’s disease has been met with resistance, but recent FDA statements reinforce the agency’s position on trial design. This dynamic encapsulates broader tensions in balancing patient safety, scientific rigor, and ethical considerations in advanced therapies.
Mar 5, 2026The burgeoning quantity of patient health data generated daily opens new opportunities and challenges. A policy group has proposed a novel framework to manage this data as a public utility to ensure patient rights and improve health research transparency and quality.
Mar 5, 2026Tracy Beth Høeg, currently acting director of FDA’s Center for Drug Evaluation and Research, is seeking to hire Adam Urato, a vaccine advisor to the CDC known for his skepticism of antidepressant use during pregnancy. This recruitment highlights ongoing debates and perspectives influencing FDA policy and drug evaluation.
Mar 3, 2026Intellia Therapeutics faced a setback last October when the FDA paused its CRISPR gene therapy studies after a patient experienced life-threatening enzyme elevations leading to death. After a thorough investigation and safety evaluation, the FDA has now fully lifted the hold, allowing Intellia to proceed with its late-stage clinical programs, marking a significant milestone in CRISPR therapeutic development.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.